Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week’s blog covers the latest myeloma research from September-October 2026. It includes a review on BCMA-targeted immunotherapy in early relapsed/refractory multiple myeloma, a study that identifies spatial transcriptomics in suppressive, T-cell–excluded tumor microenvironment in extramedullary myeloma, and more. Additionally, get the latest on myeloma clinical trials, a recommendation from the European Medicine Agency’s CHMP, and a drug approval from the European Commission. READ THE BLOG.
The International Myeloma Foundation (IMF) recently announced the launch of the US Myeloma Network (USMN) — a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuring more patients benefit from breakthrough therapies. Johnson & Johnson joins this initiative as the network’s first industry collaborator, with Sarah Cannon Development Innovations, LLC (Sarah Cannon Research Institute’s CRO) providing the infrastructure and operational expertise needed to deliver clinical trials across participating USMN sites. The USMN will focus on clinical trials with the potential to change clinical practice across care settings, accelerating the delivery of innovative therapies and new treatment approaches to patients. Read the full press release to learn more. READ THE PRESS RELEASE.
On Friday, October 23, the European Commission (EC) approved an expanded indication for TECVAYLI® (teclistamab) monotherapy for adults with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy. The approval introduces another treatment option in the second-line setting, following the EC’s August 2026 approval of teclistamab in combination with daratumumab. The decision is supported by results from the phase 3 MajesTEC-9 trial (NCT05572515), which demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared with standard-of-care regimens. READ THE NEWS ARTICLE.
The IMF offers Myeloma Community Workshops (MCWs), which are shorter, yet still robust, programs in cities across the U.S. Learn more about MCWs in San Diego, CA; and Phoenix, CA; or about an upcoming Virtual MCW. LEARN MORE HERE.
When you volunteer to organize a community fundraiser for the IMF, you receive support and guidance from the IMF's Development Team. Whether it's a 5K Walk/Run, a bake sale, or a simple letter-writing campaign, we're here to help you.
